COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,168 Articles (22,703 medRxiv, 8,465 bioRxiv)

Most recent first Previous |  Page 1833: Articles 18321-18330  | Next

Identification of a conserved neutralizing epitope present on spike proteins from highly pathogenic coronaviruses
Huang, Y., Nguyen, A. W., Hsieh, C.-L., Silva, R., Olaluwoye, O. S., Wilen, R., Kaoud, T. S., Azouz, L. R., Qerqez, A. N., Le, K. C., Bohanon, a. L., DiVenere, A. M., Liu, Y., Amengor, D., Dalby, K., D'Arcy, S., McLellan, J. S., Maynard, J. A.
10.1101/2021.01.31.428824 — Posted: 2021-02-01
Environmentally-induced mdig is a major contributor to the severity of COVID-19 through fostering expression of SARS-CoV-2 receptor NRPs and glycan metabolism
Chen, F.
10.1101/2021.01.31.429010 — Posted: 2021-02-01
Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite a lack of an antiviral effect
Foo, C. S., Abdelnabi, R., Kaptein, S. J. F., Zhang, X., ter Horst, S., Mols, R., Delang, L., Rocha-Pereira, J., Coelmont, L., Leyssen, P., Dallmeier, K., Vergote, V., Heylen, E., Vangeel, L., Chatterjee, A. K., Annaert, P., Augustijns, P., De Jonghe, S., Jochmans, D., Weynand, B., Neyts, J.
10.1101/2021.02.01.429108 — Posted: 2021-02-01
Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology.
Ryan, K. A., Schewe, K. E., Crowe, J., Fotheringham, S. A., Hall, Y., Humphreys, R., Marriott, A. C., Paterson, J., Rayner, E., Salguero, F. J., Watson, R. J., Whittaker, C. J., Carroll, M. W., Dibben, O.
10.1101/2021.02.01.429110 — Posted: 2021-02-01
Identification of anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) oxysterol derivatives in vitro
Ohashi, H., Wang, F., Stappenbeck, F., Tsuchimoto, K., Kobayashi, C., Saso, W., Kataoka, M., Kuramochi, K., Muramatsu, M., Suzuki, T., Sureau, C., Takeda, M., Wakita, T., Parhami, F., Watashi, K.
10.1101/2021.01.31.429001 — Posted: 2021-02-01
Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2'-O-methyl transfer by SARS-CoV-2 nsp16
Minasov, G., Rosas-Lemus, M., Shuvalova, L., Inniss, N. L., Brunzelle, J. S., Daczkowski, C. M., Hoover, P., Mesecar, A. D., Satchell, K. J.
10.1101/2021.01.31.429023 — Posted: 2021-02-01
Expression of human ACE2 N-terminal domain, part of the receptor for SARS-CoV-2, in fusion with maltose binding protein, E. coli ribonuclease I and human RNase A
Xu, S.-y., Fomenkov, A., Chen, T.-H., Yigit, E.
10.1101/2021.01.31.429007 — Posted: 2021-02-01
Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells
Pickard, A., Calverley, B. C., Chang, J., Garva, R., Lu, Y., Kadler, K. E.
10.1101/2021.01.31.428851 — Posted: 2021-02-01
Emergence of universality in the transmission dynamics of COVID-19
Paul, A., Bhattacharjee, J. K., Pal, A., Chakraborty, S.
10.1101/2021.01.29.21250750 — Posted: 2021-02-01
Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine
Krammer, F., Srivastava, K., PARIS team, , Simon, V.
10.1101/2021.01.29.21250653 — Posted: 2021-02-01 Discussion: Onsite | Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).